Compounds > 1-(5-isoquinolinesulfonyl)-2-methylpiperazine

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and 3-nitrotyrosine

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with 3-nitrotyrosine in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Edgley, AJ; Fujii, Y; Jenkins, MJ; Joshi, M; Kelly, DJ; Pearson, JT; Schwenke, DO; Shirai, M; Sonobe, T; Tsuchimochi, H; Umetani, K; Waddingham, MT; Yoshimoto, M1
Batteux, F; Bei, Y; Chéreau, C; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Le-Dong, NN; Nicco, C; Tiev, KP1

Other Studies

2 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and 3-nitrotyrosine

ArticleYear
Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.
    Cardiovascular diabetology, 2013, Aug-01, Volume: 12

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Angiography; Coronary Circulation; Coronary Vessels; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Epoprostenol; Fibrosis; Male; Microcirculation; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Tyrosine; Vasoconstriction; Vasodilation; Vasodilator Agents

2013
RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
    Experimental lung research, 2016, Volume: 42, Issue:1

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Disease Models, Animal; Female; Hypochlorous Acid; Lung; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Pneumonia; Pulmonary Fibrosis; rho-Associated Kinases; Scleroderma, Systemic; Skin; Smad2 Protein; Smad3 Protein; Tyrosine

2016